Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
Why the study?
Cardiovascular imaging is an important tool in baseline risk assessment and detection of CV disease in oncology patients receiving cardiotoxic cancer therapies.
Population
Cancer patients receiving cardiotoxic cancer therapies
Design
Position statement
Authors
Discussion
Loading...
Member takes
Implication
Cardiovascular imaging now standard for cardiotoxicity monitoring in cancer therapy; reinforces consensus guidelines with updated protocols.
Key Points
- Baseline risk assessment and surveillance rely on echocardiography alongside cardiac magnetic resonance to detect cardiovascular disease during cardiotoxic cancer therapies.
- Evaluation protocols prioritize global longitudinal strain and three-dimensional ejection fraction to identify subclinical ventricular dysfunction across treatment phases.
- Standardized imaging pathways guide monitoring during anthracycline chemotherapy and immune checkpoint inhibitors, supporting long-term toxicity detection in survivors.
Structured PICO
P
Population
Cancer patients receiving cardiotoxic cancer therapies
I
Intervention
Cardiovascular imaging (echocardiography, cardiac magnetic resonance, nuclear cardiac imaging, and computed tomography)
This position statement outlines standardized protocols and surveillance algorithms for cardiovascular imaging in cancer patients undergoing cardiotoxic treatments.
Cite This Study
Čelutkienė et al. (2020) conducted a review in Cancer patients receiving cardiotoxic therapies. Cardiovascular imaging was evaluated. Cardiovascular imaging, including echocardiography and cardiac magnetic resonance, is recommended for baseline risk assessment and surveillance of cancer patients receiving cardiotoxic therapies.